On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO, July 9, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACROBiosystems, the summit was uniquely designed as an international roadshow and licensing matchmaking platform dedicated...
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company presented its latest advances in AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody development platform at Booth...
Vermon launches Vermon Group, accelerating its growth and expanding its offerings
Vermon Group opens a new chapter with the acquisition of Moduleus, the opening of TransducerWorks' new U.S. manufacturing facility, and the launch of a coordinated Group platform designed to move faster, deliver more, and stay close to customers. TOURS, France, July 8, 2026 /PRNewswire/ -- Vermon Group, an international ultrasound technology...
Altruist Biologics’ Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HANGZHOU, China, July 8, 2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development...
Global Care Economy Set to Create Significant Growth Opportunities as Care-Dependent Population Reaches up to 4.6 Billion by 2035
Rapid population ageing and care worker shortages are accelerating demand for next-generation care infrastructure, AgeTech, and integrated care ecosystems LONDON, July 8, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, The Global Care Economy, Transformations and Opportunities to 2035, reveals that demographic change, mounting healthcare workforce shortages, and accelerating digital innovation are reshaping the global care economy and...
Seegene Launches Industry’s First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-informed clinical decision-making. The company is recognized as...
BB Energy Secures Three Additional South Sudan Crude Oil Cargoes
LONDON, July 8, 2026 /PRNewswire/ -- BB Energy secures three additional crude oil cargos from the Republic of South Sudan. BB Energy is pleased to announce that it has been awarded three additional crude oil cargoes by the Republic of South Sudan, scheduled for delivery in August, September and November 2026....
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and...
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase...
Merz Aesthetics Presents Ultherapy Mask – PDRN Peptide Radiance and Launches its 2026 Campaign at the Ultherapy PRIME Soirée in Malaysia
Merz Aesthetics introduces its 2026 campaign "See My Skin, Lift My Way", celebrating individuality, authenticity and the belief that every skin journey is unique, during an event in Malaysia Media, key opinion leaders and aesthetic physicians from across the region were able to experience the Ultherapy Mask - PDRN Peptide...
